M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer

Lili Cao, Xiaofang Che, Xueshan Qiu, Zhi Li, Bowen Yang, Shuo Wang, Kezuo Hou, Yibo Fan, Xiujuan Qu, Yunpeng Liu, Lili Cao, Xiaofang Che, Xueshan Qiu, Zhi Li, Bowen Yang, Shuo Wang, Kezuo Hou, Yibo Fan, Xiujuan Qu, Yunpeng Liu

Abstract

Background: Lung cancer is the leading cause of cancer-related death worldwide. Although the macrophages can affect the development of tumor, the contribution of macrophages to the prognosis of non-small-cell lung cancer (NSCLC) is still controversial. Moreover, anti-PD-1 therapy can redirect macrophages from an M2 to an M1 phenotype, suggesting that tumor PD-L1 may affect the prognostic role of macrophages. Therefore, in this study, we aimed to display a macrophage landscape to clarify the function of macrophages, considering the localization and polarization of the macrophages, and evaluate the effect of M2 macrophages and tumor PD-L1 in combination on the prognosis of NSCLC. Methods: We performed multiplex quantitative immunofluorescence staining of pan-cytokeratin (CK), CD68, CD163, PD-L1, and DAPI on one tissue specimen simultaneously from 137 NSCLC patients. Results: M2 macrophages, involved marginM2 (M2 macrophages in tumor stroma), and centralM2 (M2 macrophages infiltrating into tumor islets) increased as the tumor stage increased. More macrophages were found in lung squamous cell carcinoma (LUSC) patients, patients with wild-type EGFR, and smokers than in patients with lung adenocarcinoma (LUAD), patients with EGFR mutations, and non-smokers. Infiltration of centralM2 was an independent prognostic factor of poor overall survival (OS) and disease-free survival (DFS) for NSCLC patients (P<0.05), which was superior to total macrophages and total M2 macrophages. Moreover, patients with centralM2lessPD-L1- tumors showed the best OS and DFS, while the patients with centralM2morePD-L1+ tumors showed the worst OS and DFS, and the two groups with centralM2lessPD-L1+ and centralM2morePD-L1- were in the middle (P=0.002, 0.034, respectively). Conclusion: Tumor islet-infiltrating M2 macrophages influence the prognosis of NSCLC patients. The analysis of M2 macrophages and tumor PD-L1 in combination may enhance the accuracy of prognostic prediction. This study provides a new understanding of macrophages in the development of NSCLC through the analysis of macrophage landscape.

Keywords: PD-L1; macrophage; microenvironment; non-small-cell lung cancer; polarization; prognosis.

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
The macrophage landscape in the microenvironment of NSCLC. (A) A representative image using multiple quantitative fluorescence staining. Blue, DAPI; red, CK; green, CD68; orange, CD163; yellow, PD-L1. Scale bars =100 μm. (B) Quantity of cell subpopulations normalized to the total cell numbers in TIME. (C) Proportion of macrophage distribution in stroma (green) and tumor islets (red) of 137 patients in NSCLC microenvironment. Each column represents a patient. (D) A representative image of macrophages distributed in the tumor microenvironment. Blue, DAPI; red, CK; green, CD68; orange, CD163. Scale bars =100μm. Abbreviations: TC, tumor cells; M, total macrophages; M1, M1 macrophages; M2, M2 macrophages; NSCLC, non-small-cell lung cancer; TIME, tumor immune microenvironment.
Figure 2
Figure 2
Distribution of macrophages in different tumor stages. (A-C) Represents the global distribution of macrophages. (D-F) Represents the distribution of macrophages in tumor islet. (G-I) Represents the distribution of macrophages in the stroma. Density = cell number/3.6×10, m2. P<0.05 indicates statistical significance. Abbreviations: M, total macrophages; M1, M1 macrophages; M2, M2 macrophages.
Figure 3
Figure 3
Quantity of macrophages in patients with different clinicopathological parameters. (A-C) Density of total macrophages (A), M1 macrophages (B), M2 macrophages (C) in patients with different pathological types. (D-F) Density of total macrophages (D), M1 macrophages (E), M2 macrophages (F) in patients with different EGFR status. (G-I) Density of total macrophages (G), M1 macrophages (H), M2 macrophages (I) in patients with different smoking history. (J-L) Proportion of M2 macrophages to total macrophages in patients with different pathological types (J), EGFR status (K) and smoking history (L). Density = cell number/3.6×105, m2. P<0.05 indicates statistical significance. Abbreviations: M, total macrophages; M1, M1 macrophages; M2, M2 macrophages; M2/M, Proportion of M2 macrophages to total macrophages; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; EGFR-MT, EGFR mutation; EGFR-WT, EGFR wild-type; S, smoker; NS, nonsmokers.
Figure 4
Figure 4
Overall survival (OS) analysis for macrophages of different polarization states and locations. Notes: (A-C) Kaplan–Meier curve of the relationship between the total macrophages (M) (A), total M2 macrophages (M2) (B), total M1 macrophages (M1) (C) and the OS of NSCLC patients. (D-F) Kaplan–Meier curve of the relationship between the macrophages infiltrating in tumor islets (centralM) (D), M2 macrophages infiltrating in tumor islets (centralM2) (E), M1 macrophages infiltrating in tumor islets (centralM1) (F) and the OS of NSCLC patients. (G-I)Kaplan–Meier curve of the relationship between the macrophages in stroma (marginM) (G), M2 macrophages in stroma (marginM2) (H), M1 macrophages in stroma (marginM1) (I) and the OS of NSCLC patients. (J)Kaplan–Meier curve of the relationship between the ratio of M2 macrophages infiltrating in tumor islets to M2 macrophages infiltrating in stroma (centralM2/marginM2) and the OS of NSCLC patients.less: low infiltration; more: high infiltration.
Figure 5
Figure 5
Disease-free survival analysis (DFS) for macrophages of different polarization states and locations. Notes: (A-C) Kaplan–Meier curve of the relationship between the total macrophages (M) (A), total M2 macrophages (M2) (B), total M1macrophages (M1) (C) and the DFS. (D-F) Kaplan–Meier curve of the relationship between the macrophages infiltrating in tumor islets (centralM) (D), M2 macrophages infiltrating in tumor islets (centralM2) (E), M1 macrophages infiltrating in tumor islets (centralM1) (F) and the DFS. (G-I) Kaplan–Meier curve of the relationship between the macrophages infiltrating in stroma (marginM) (G), M2 macrophages infiltrating in stroma (marginM2) (H), M1 macrophages infiltrating in stroma (marginM1) (I) and the DFS.(J)Kaplan–Meier curve of the relationship between the ratio of M2 macrophages infiltrating in tumor islets to M2 macrophages infiltrating in stroma (centralM2/marginM2) and the DFS. less: low infiltration; more: high infiltration.
Figure 6
Figure 6
Prognostic analysis of M2 macrophages and tumor PD-L1 combination of NSCLC. (A) Kaplan–Meier curve of the relationship between the combination of M2 macrophages and tumor PD-L1, and the overall survival (OS). (B) Kaplan–Meier curve of the relationship between the combination of M2 macrophages and tumor PD-L1 and the disease-free survival (DFS). (C) Kaplan–Meier curve of the relationship between the combination of centralM2 macrophages and tumor PD-L1, and the OS. (D) Kaplan–Meier curve of the relationship between the combination of marginM2 macrophages and tumor PD-L1, and the DFS. Notes: M2lessPD-L1-: low infiltration of M2 macrophages and tumor PD-L1 negative; M2lessPD-L1+: low infiltration of M2 macrophages and tumor PD-L1 positive; M2morePD-L1-: high infiltration of M2 macrophages and tumor PD-L1 negative; M2morePD-L1+: high infiltration of M2 macrophages and tumor PD-L1 positive. centralM2lessPD-L1-: low infiltration ofcentralM2 macrophages and tumor PD-L1 negative; centralM2lessPD-L1+: low infiltration of centralM2 macrophages and tumor PD-L1 positive; centralM2morePD-L1-: high infiltration of centralM2 macrophages and tumor PD-L1 negative; centralM2morePD-L1+: high infiltration of centralM2 macrophages and tumor PD-L1 positive.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262
    1. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508. doi:10.1016/S1470-2045(16)30498-3
    1. Borghaei H, Langer CJ, Gadgeel S, et al. 24-month overall survival from KEYNOTE-021 Cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2019;14(1):124–129.
    1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
    1. Morrison C. Immuno-oncologists eye up macrophage targets. Nat Rev Drug Discov. 2016;15(6):373–374.
    1. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8(8):618–631.
    1. Nakao S, Kuwano T, Tsutsumi-Miyahara C, et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest. 2005;115(11):2979–2991.
    1. Lin EY, Li JF, Bricard G, et al. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol. 2007;1(3):288–302.
    1. Chen P, Huang Y, Bong R, et al. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin Cancer Res. 2011;17(23):7230–7239. doi:10.1158/1078-0432.CCR-11-1354
    1. Guruvayoorappan C. Tumor versus tumor-associated macrophages: how hot is the link? Integr Cancer Ther. 2008;7(2):90–95. doi:10.1177/1534735408319060
    1. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008;13(3):206–220. doi:10.1016/j.ccr.2008.01.034
    1. Gocheva V, Wang HW, Gadea BB, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010;24(3):241–255. doi:10.1101/gad.1874010
    1. Gil-Bernabe AM, Ferjancic S, Tlalka M, et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood. 2012;119(13):3164–3175. doi:10.1182/blood-2011-08-376426
    1. Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006;203(4):871–881. doi:10.1084/jem.20050930
    1. Takanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology. 1999;57(2):138–142. doi:10.1159/000012021
    1. Chen JJ, Yao PL, Yuan A, et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 2003;9(2):729–737.
    1. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996;56(20):4625–4629.
    1. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol. 2000;17(3):445–451.
    1. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000;60(20):5857–5861.
    1. Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer. 2003;97(4):960–968. doi:10.1002/cncr.11152
    1. Johnson SK, Kerr KM, Chapman AD, et al. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer. 2000;27(1):27–35.
    1. Toomey D, Smyth G, Condron C, et al. Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: no association with prognosis identified in 3-year follow-up. Int J Cancer. 2003;103(3):408–412. doi:10.1002/ijc.10836
    1. Yuan A, Hsiao YJ, Chen HY, et al. Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression. Sci Rep. 2015;5:14273. doi:10.1038/srep14273
    1. Sun Y, Xu S. Tumor-associated CD204-positive macrophage is a prognostic marker in clinical stage i lung adenocarcinoma. Biomed Res Int. 2018;2018:8459193.
    1. Zhang B, Yao G, Zhang Y, et al. M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo). 2011;66(11):1879–1886.
    1. Hirayama S, Ishii G, Nagai K, et al. Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of Cd204-positive macrophages to the tumor-promoting microenvironment. J Thorac Oncol. 2012;7(12):1790–1797. doi:10.1097/JTO.0b013e3182745968
    1. Li Z, Maeda D, Yoshida M, et al. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer. Lung Cancer. 2018;123:127–135. doi:10.1016/j.lungcan.2018.07.015
    1. Kim DW, Min HS, Lee KH, et al. High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer. 2008;98(6):1118–1124. doi:10.1038/sj.bjc.6604256
    1. Jackute J, Zemaitis M, Pranys D, et al. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunol. 2018;19(1):3. doi:10.1186/s12865-018-0241-4
    1. Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495–499. doi:10.1038/nature22396
    1. Dhupkar P, Gordon N, Stewart J, Kleinerman ES. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med. 2018;7(6):2654–2664. doi:10.1002/cam4.1518
    1. Guo W, Zhang F, Shao F, et al. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. Hum Pathol. 2019;84:291–298.
    1. Troiano G, Caponio VCA, Zhurakivska K, et al. High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: a meta-analysis of the literature. Cell Prolif. 2019;52(2):e12537.
    1. Yu H, Chen Z, Ballman KV, et al. Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early-stage squamous cell lung carcinoma. J Thorac Oncol. 2019;14(1):25–36.
    1. Okuma Y, Hishima T, Kashima J, Homma S. Correction to: high PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer. Cancer Immunol Immunother. 2018;67(9):1477–1479. doi:10.1007/s00262-018-2215-z
    1. Xia H, Shen J, Hu F, et al. PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients. Clin Chim Acta. 2017;469:191–194. doi:10.1016/j.cca.2017.02.005
    1. Berntsson J, Eberhard J, Nodin B, Leandersson K, Larsson AH, Jirstrom K. Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: relationship with sidedness and prognosis. Oncoimmunology. 2018;7(8):e1465165. doi:10.1080/2162402X.2018.1490854
    1. Wang Y, Zhu C, Song W, Li J, Zhao G, Cao H. PD-L1 expression and CD8(+) T cell infiltration predict a favorable prognosis in advanced gastric cancer. J Immunol Res. 2018;2018:4180517. doi:10.1155/2018/4180517
    1. Zhu Q, Cai MY, Chen CL, et al. Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. Oncoimmunology. 2017;6(5):e1312240. doi:10.1080/2162402X.2017.1312240
    1. Jung HI, Jeong D, Ji S, et al. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat. 2017;49(1):246–254. doi:10.4143/crt.2016.066
    1. Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–162. doi:10.1097/JTO.0000000000000033
    1. Garassino MC, Gelibter AJ, Grossi F, et al. Italian nivolumab expanded access program in nonsquamous non-small cell lung cancer patients: results in never-smokers and EGFR-mutant patients. J Thorac Oncol. 2018;13(8):1146–1155.
    1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
    1. Kobayashi H, Omori S, Nakashima K, et al. Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. Int J Clin Oncol. 2017;22(4):690–697.
    1. Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2980–2987.
    1. Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol. 2017;12(2):403–407.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅